What question did this study set out to answer?

To evaluate real-world prescription rates, longitudinal trends, and clinical predictors of hydralazine-isosorbide dinitrate therapy in eligible patients hospitalized with heart failure and reduced ejection fraction.

August 22, 2013Journal of the American Heart AssociationOpen Access

Use of Hydralazine‐Isosorbide Dinitrate Combination in African American and Other Race/Ethnic Group Patients With Heart Failure and Reduced Left Ventricular Ejection Fraction

View Full Paper

Ask AI

Bookmark

Why the study?

What are the prescription rates, temporal trends, and predictors of use of hydralazine-isosorbide dinitrate (H-ISDN) therapy in eligible patients with HFrEF?

Population

54,622 patients admitted with HFrEF and discharged home from 207 hospitals participating in the Get With The…

Design

Cohort

Authors

HGHarsh GolwalaLouisiana State University UTUdho ThadaniUniversity of Oklahoma Health Sciences Center LLLi LiangCentral South University

Discussion

Member takes

Implication

H-ISDN remains underused in eligible African American HFrEF patients; leaves open optimal strategies to improve adoption.

Key Points

To evaluate real-world prescription rates, longitudinal trends, and clinical predictors of hydralazine-isosorbide dinitrate therapy in eligible patients hospitalized with heart failure and reduced ejection fraction.
Analyzed 54,622 patients admitted with heart failure and reduced ejection fraction (<40%) and discharged home across 207 hospitals in the Get With The Guidelines-Heart Failure registry between April 2008 and March 2012.
Assessed discharge prescription rates of hydralazine-isosorbide dinitrate overall and among eligible African American patients, using multivariable modeling to identify clinical and sociodemographic predictors of use.
Only 22.4% of eligible African American patients (2,500 of 11,185) and 12.6% of the overall eligible population (5,115 of 43,498) received hydralazine-isosorbide dinitrate at discharge.
Prescription rates increased over the study period from 16% to 24% among African Americans and from 10% to 13% across the overall cohort.
Hydralazine-isosorbide dinitrate use was associated with younger age, male sex, Black or Hispanic ethnicity, diabetes, hypertension, anemia, and renal insufficiency, whereas being uninsured was linked to lower use among African American patients.

Structured PICO

What are the prescription rates, temporal trends, and predictors of use of hydralazine-isosorbide dinitrate (H-ISDN) therapy in eligible patients with HFrEF?

Population

54,622 patients admitted with HFrEF (LVEF <40%) and discharged home from 207 hospitals participating in the Get With The Guidelines-Heart Failure registry from April 2008 to March 2012, including 11,185 African American patients eligible for H-ISDN therapy.

Intervention

Hydralazine-isosorbide dinitrate (H-ISDN) therapy at discharge

Outcome

Prescription rates, temporal trends, and predictors of use of H-ISDN among eligible patients at discharge

Despite guideline recommendations, hydralazine-isosorbide dinitrate is significantly underutilized in eligible African American patients with HFrEF, with less than one-fourth receiving the therapy at discharge.

Cite This Study

Golwala et al. (2013) studied this question.

synapsesocial.com/papers/6a70a292f44fa9f079de5034 https://doi.org/10.1161/jaha.113.000214

Topics

HFrEF treatment Heart failure

View Full Paper

Ask AI

Bookmark

Use of Hydralazine‐Isosorbide Dinitrate Combination in African American and Other Race/Ethnic Group Patients With Heart Failure and Reduced Left Ventricular Ejection Fraction

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Use of Hydralazine‐Isosorbide Dinitrate Combination in African American and Other Race/Ethnic Group Patients With Heart Failure and Reduced Left Ventricular Ejection Fraction

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider